Liz Barrett, CEO, UroGen Pharma: A Speciality Calling in Cancer

Stepping Out in Oncology

Pharm Exec September 2020

Pharm Exec's September 2020 Online Edition

Elaine Quilici is Pharmaceutical Executive's Senior Editor. Email her at equilici@mmh.com

Podcasts

George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.

Episode 65: Creating a Path for Innovation

Articles

A technology-enabled solution combining predictive analytics integrated with real-time commercial services for the life sciences sector.

EVERSANA Announces Launch of ACTICS

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Our Launch-Time Menu

Ed Shankman is  Chief Creative Officer, Cyan Health.

Brand positioning that targets HCPs is often irrelevant to the payer mindset.
Fortunately, market access teams have an option, writes Ed Shankman.

The Value Cornerstone: Bridging the Pharma Marketing Gap

Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.

Drug Launch: Winning the Evidence Battle

Jill Wechsler is Pharm Exec's Washington Corespondent

President Trump has taken on the pharma industry in a surprise move making significant cuts in reimbursement for drugs covered by Medicare. 

Trump Escalates Drug Pricing War

The key factors behind the sector’s strong surge in new equity fundraisings.

Biopharma Capital Markets Sizzle in 2020

Orphan drug incentives set to remain in place in Europe.

Key Support for Rare Disease Medicine Scheme

Tasked with setting up framework for essential medicine program. 

FDA in Hot Seat on ‘Buy American’ Drug Policy

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

Unlocked Potential — ‘Keying’ in On New-Era Engagement

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.

Vaccine Supply: Trusting in Blockchain

Creating behavioral change in the pharma workplace.

The Importance of Embracing Diversity

Staying the Course in Product Launch

A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.


ESG objectives are integral to long-term biopharma strategy.

Sustainable Long-Term Planning

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Taking Biopharma’s Pulse in a Tough 2020

Sheila Thorne is the President/CEO, Multicultural Healthcare Marketing Group, LLC, and is one of the nation's leading experts in multicultural healthcare marketing. For more information logo onto www.sheilathorne.com

Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?

The Cultural Deficit in the Pharma Industry in the Era of COVID-19

Peter Kohut is Director of Drug Safety at Arriello and an experienced EU QPPV. He began his career in biochemical research, before entering the pharmaceutical industry where he has worked in both clinical trials and post-marketing safety roles. Arriello is a global provider of innovative, high-impact market access, regulatory affairs & pharmacovigilance solutions and services for pharma and biotech firms primarily in Europe and North America.

Peter Kohut analyses the findings of a survey on how life sciences companies are capitalizing on opportunities to transform workload and data quality management using the latest smart technology.

Streamlining Pharmacovigilance: Why the Inertia?

Review platform launches in light of new research which reveals that 93% lack trust in pharma companies.

DrugsDisclosed.com Launches ‘Medication Trustpilot’ to Amplify Patient Voices 

Dr. Wolfram Lux is a Senior Director and Dr. Simone Seiter is a Partner in the global Pharma & Biotech practice within Simon-Kucher & Partners Life Sciences Division (Frankfurt, Germany).

Looking at four building blocks of success, Wolfram Lux and Simone Seiter investigate what it takes to win and be successful when commercializing an orphan drug